Professional Documents
Culture Documents
DOI 10.1007/s40273-015-0280-0
between December 2012 and January 2013. Women who until menopause first for oral treatment, and then LNG-
were menstruating but did not necessarily have experience IUS. A payment scale, which presents respondents with a
of menorrhagia or its treatments were sought, so all women range of monetary values, was used to elicit WTP values as
attending an appointment were approached to complete a it has a higher completion rate than other methods that can
booklet questionnaire, either in the clinic or at home, and be used in a postal questionnaire [12]. The payment scale
provided written informed consent to participate. Respon- was derived from a previous applied WTP study [12], and
dents who took the questionnaire home to complete were used a range from £0 to £500, which was considered to be
given a stamped addressed envelope. Women were asked most suitable, as the questionnaire asked respondents to
to value the two pharmaceutical treatments of LNG-IUS provide a monthly WTP value. An open-ended option for
and oral treatment. values greater than £500 was offered. Following the WTP
question, we asked respondents to outline the reasons for
2.2 Outcome Measures their WTP values in an open-ended question to assess the
validity of the WTP responses. The respondents were then
WTP is elicited from the ex-ante perspective. Individuals asked to indicate whether they found the WTP question
are asked to express in monetary terms how much they difficult to answer, and to provide reasons for their re-
value a good or a service that leads to a change in outcome sponse. The time frame of payment ‘up until menopause’
[9]. In this context, maximum WTP values were derived was explicitly stated to ensure that WTP values were not
prior to the change in outcome occurring, from respondents overestimated [13]. The questionnaire included a reminder
who are ‘at risk’ of the condition, or ‘at risk’ of requiring to consider the amount that they can afford to pay to ensure
treatment. Given the UK is a tax-funded system that offers that the responses obtained were realistic and within the
healthcare ‘free at the point of use’, we designed the WTP respondent’s means [14]. The time period was intuitive
study to elicit the views of the at-risk population. The ra- given the nature of the condition. The monthly payment
tionale being that because society is funding the healthcare time frame was used because women generally pay
system, it is the views of those at risk that should be sought. monthly (or every 3 months) for prescriptions for menor-
The questionnaire booklet was reviewed by clinical rhagia, for sanitary protection and will experience the
experts in menorrhagia, psychologists and health econo- benefits of treatment on a monthly basis.
mists for face and content validity. Maximum WTP values The booklet questionnaire is presented in the online
were elicited for both LNG-IUS and oral treatment using a resource.
self-complete booklet questionnaire. The booklet captured
data on WTP and sociodemographic details. 2.3 Cost and Resource Use
A description of menorrhagia (without treatment) was
first presented and was based on the domains of the dis- Given that an ex-ante perspective was adopted, the women
ease-specific quality-of-life Menorrhagia Multi-attribute were not typically being treated with LNG-IUS or oral
Assessment Scale (MMAS). This measure incorporates treatment, and therefore primary cost data were not avail-
both the health and non-health outcomes associated with able. The costs were consequently derived using the
menorrhagia and consists of six attributes, ‘practical diffi- ECLIPSE trial data as the most appropriate available
culties, ‘social life’, ‘psychological health’, ‘physical source and also to enable comparability between the cost-
health and well-being’, ‘work/daily routine’ and ‘family utility analysis alongside the ECLIPSE trial and our cost-
life/ relationships’ [10]. We used baseline MMAS data benefit analysis [6]. Briefly, the general healthcare costs for
from a recent trial (ECLIPSE, ISRCTN86566246) to gen- both treatments included healthcare staff costs and the cost
erate the description. We then presented a scenario de- of the treatments. The costs of LNG-IUS and oral treatment
scribing the expected average ‘outcome’ associated with were estimated using the British National Formulary [15].
the two treatments, LNG-IUS (termed Mirena in the sce- Staff costs were calculated using the nationally recognised
narios) and oral treatment, using average follow-up MMAS reference costs [16]. All costs are reported in 2011 prices in
data from the ECLIPSE trial [11]. UK (£) sterling using the UK hospital and community
Using the same method the scenarios for the outcomes health services index [16]. The overall costs for both LNG-
associated with LNG-IUS and oral treatments, using the IUS and oral treatment at the 2-year time point in the
6-month ECLIPSE MMAS data, were generated. Infor- ECLIPSE trial included crossover between treatment arms,
mation describing the process of care was also described in as the analysis within the trial was ‘intention to treat’. The
the treatment scenarios (see online resource for method average costs of LNG-IUS and oral treatment per person
used for scenario development). were taken from the average results of a trial-based eco-
Respondents were asked for their preferred treatment, nomic evaluation, where a decision model was used as the
and their maximum monthly out-of-pocket WTP value up basis for the evaluation, and were reported to be £430 and
960 S. Sanghera et al.
£330, respectively [6]. All costs are from a UK National treatment are applied, treatment cross-over is not
Health Service perspective. A societal perspective for costs considered. Table 1 outlines the cost data used in the
was considered but was not used to enable a comparison sensitivity analysis. As oral treatment comprises a range
between previous analyses using EQ-5D and SF-6D [6]. of pharmaceutical treatments, the average cost of oral
treatment was weighted according to the frequency with
2.4 Analysis which each treatment is prescribed [6].
LNG-IUS
Consultation (GP 10 min) 26.67 Curtis 2011 (16)/expert opinionb
Insertion
GP (20 min) 53.33 Curtis 2011 (16)/expert opinion
Practice nurse (20 min) 17.00 Curtis 2011 (16)/expert opinion
Device cost 88.00 BNF 62 (15)
Sterile pack (insertion) 21.63 NICE (4) (inflated to 2011)
Follow-up
6-week review: (GP 10 min) 26.67 Curtis 2011 (16)/expert opinion
3 month review: (GP 10 min) 26.67 Curtis 2011 (16)/expert opinion
a c
Unit cost (£) Frequency Source
Oral treatment
Progestogen (Cerazette) 8.68 21 BNF 62 (15)
Tranexamic acid (Cyclokapron) 14.30 19 BNF 62 (15)
Mefenamic acid (Ponstan) 15.72 8 BNF 62 (15)
Norethisterone 2.18 2 BNF 62 (15)
Combined oral contraceptive (Microgynon) 2.82 1 BNF 62 (15)
Methoxyprogesterone acetate injections (Depo-provera) 6.01 6 BNF 62 (15)
Consultation: (GP 10 min) 26.67 Curtis 2011 (16)/expert opinion
Review of medication (GP 10 min) 26.67 Curtis 2011 (16)/expert opinion
BNF British national formulary, GP general practitioner, LNG-IUS levonorgestrel-releasing intrauterine system, NICE National Institute for
Health and Care Excellence
a
The cost year is 2011
b
Expert opinion refers to clinical experts in menorrhagia (JG, JK)
c
The frequency is used to calculate the weighted average cost of oral treatment. The values are derived from data in a model-based economic
evaluation [6]
Table 2 Base-case results: Intervention WTP Cost NPV (WTP - cost) INB (NPV oral - NPV LNG-IUS)
mean WTP and cost of
treatment LNG-IUS £365 £433 £-68
Oral treatment £372 £326 £45 £113
Mean difference £-7 £107
Cost data are reported in UK (£) sterling and the cost year is 2011. Costs are rounded to the nearest whole
number
Cost data relate to the results of the economic evaluation alongside the ECLIPSE trial [6], which are based
on an ‘intention-to-treat’ analysis. The initial costs used in the economic evaluation alongside the ECLIPSE
trial are described in Table 1
INB incremental net benefit, LNG-IUS levonorgestrel-releasing intrauterine system, NPV net present value,
WTP willingness to pay
NPV than LNG-IUS and the incremental net benefit ex- protest answers, which relate to the individual refusing to
ceeds zero. provide a WTP value, were identified from the qualitative
explanations offered.
3.3 Response to Outcome Measure Ninety-nine women with an average age of 37 years
provided a WTP value for LNG-IUS and oral treatment.
One hundred and ten women completed and returned the LNG-IUS was the preferred treatment (47), followed by
questionnaire. Both LNG-IUS and oral treatment received oral treatment (39) and no preference (11). Two respon-
the same number of non-responses (four in each). Seven dents did not answer the question (see online resource for
962 S. Sanghera et al.
Table 3 Sensitivity analysis: Intervention WTP Cost NPV (WTP - cost) [95 % CI] INB (NPV oral - NPV LNG-IUS)
mean WTP and cost of
treatment LNG-IUS £365 £260 £106 [£-10 to £221]
Oral treatment £372 £98 £274 [£168 to £380] £168
Mean difference £-7 £162
CI confidence interval, INB incremental net benefit, LNG-IUS levonorgestrel-releasing intrauterine system,
NPV net present value, WTP willingness to pay
Cost data are reported in UK (£) sterling and the cost year is 2011. Costs are rounded to the nearest whole
number
further information). Eighty percent of women said they valuing healthcare’. For those who did not find the val-
had experience of heavy periods at one time in their lives, uation difficult, the most commonly cited reason was ‘a
but this may not necessarily mean experience of heavy reasonable amount to pay for the expected benefits’.
periods over consecutive cycles as defined by menorrhagia.
The two most commonly cited reasons for a WTP value
were related to the ‘effect of the treatment’ and ‘afford- 4 Discussion
ability’. There were three respondents that misunderstood
the WTP question. Over a 24-month time horizon, the total cost of oral
Over 60 % of women who completed at least one WTP treatment is cheaper than LNG-IUS (£326 compared with
question said that the question was not difficult to answer. £433 respectively). The NPV of oral treatment is greater
Of those who did find the question difficult to answer, the than LNG-IUS (£45 compared with £-68, respectively).
most common reason was related to ‘not being used to Thus, oral treatment produced a positive incremental net
Exploring Cost-Benefit Analysis in Menorrhagia 963
benefit (equal to £113). On the basis of these results, oral A limitation of the exploratory study is that we did not
treatment could be recommended as the first-line treatment determine how many women from our convenience sample
for menorrhagia. had experience of the treatments for menorrhagia. This
The findings from both sensitivity analyses support the information would help to determine the extent to which
base-case analysis. The bootstrapped plots in sensitivity our sample reflects a true ex-ante perspective. The sample
analysis 1 demonstrate that oral treatment is the most likely used does to some extent reflect the ‘at-risk’ population
treatment to be cost beneficial. In sensitivity analysis 2, group, which would be made up of both women who have,
where cost data are not taken from the ECLIPSE trial de- and do not have, the condition. However, where women
cision model, which used intention-to-treat analysis but have experience of both menorrhagia and its treatments this
instead relate to the exclusive use of either LNG-IUS or does not strictly meet the ex-ante criterion.
oral treatment, both oral treatment and LNG-IUS generated The costs for the base-case analysis were taken from the
a positive NPV of £274 and £106 respectively. However, average results of a trial-based economic evaluation to
oral treatment yielded the maximum NPV and therefore enable comparability between that cost-utility analysis and
was still indicated to be the most efficient choice. our cost-benefit analysis [6]. A potential limitation of this
Therefore, the base-case analysis and sensitivity ana- approach is that the possibility of changing and stopping
lyses suggest that oral treatment is the most cost-beneficial treatment was not presented in the WTP scenario and
treatment and therefore should be recommended as the therefore would not have been considered when providing
first-choice treatment for menorrhagia in clinical practice. a WTP value. However, when using cost data that are only
In a privately financed healthcare system, the resource related to the WTP scenario the same treatment was found
allocation decision from a cost-benefit analysis is relatively to be superior. In this case, although the overall cost-benefit
straightforward as a positive NPV indicates that the inter- decision did not differ, the extent of the welfare gain
vention(s) be recommended for use in practice. In contrast, produced by oral treatment compared with LNG-IUS did
when making resource allocation decisions in a publicly vary, and was dependent on the cost data used in the cost-
funded healthcare system where a budget constraint exists, benefit analysis.
it is unlikely to be feasible that all interventions with a It was not possible to conduct a comprehensive cost-benefit
positive NPV are recommended for clinical practice [18]. analysis because societal costs were not available. Only
Under budget constraints, the aim is to maximise benefits healthcare costs were considered in this evaluation. The dif-
and therefore the interventions could be ranked against one fering perspectives across costs and benefits could bias the
another and the intervention with the greatest NPV im- results in favour of the benefits of the treatments as a broader
plemented [9]. Whilst this issue is not resolved, in this perspective is used. However, when assessing incremental net
case, we adopted the decision rule that the treatment choice present values across treatments, the impact is limited as the
that yields the maximum NPV is the most efficient and same approach is applied to both interventions assessed. In-
should be implemented. corporating societal costs, such as lost productivity and out-of-
pocket prescription fees, would not be straightforward be-
4.1 Strengths and Limitations cause of double counting. Arguably, the WTP outcome al-
ready incorporates lost productivity as the WTP scenarios
This is the first study, to our knowledge, that applies a included impact on work/daily routine. Therefore, if changes
cost-benefit analysis to compare LNG-IUS against oral in productivity are also counted on the cost side of the equa-
treatment in menorrhagia. Furthermore, a cost-benefit tion, it is possible that the benefits of treatment are double
analysis is rarely conducted and reported in the literature counted [19]. The other aspect of societal cost is the cost of
and a strength of the current analysis, is that it is based on prescriptions, which would only be relevant to oral treatment
WTP values that have been elicited from the ex-ante and the exclusion of this could be considered as bias in favour
perspective, which is theoretically preferred [9]. An ad- of oral treatment. However, we estimate this cost to be small
ditional strength is that once the questionnaires were de- and unlikely to change the treatment recommendation.
veloped, they were checked by clinical experts in Finally, we recognise the limitation associated with re-
menorrhagia, by psychologists and external health econ- porting costs in the 2011 price year and WTP values in
omists to assess and improve their face and content va- 2013. Different years of valuation are not unusual in health
lidity. Thus, rather than basing the ex-ante questionnaire economics as the utility values derived from other standard
scenarios, for menorrhagia and treatment effectiveness, measures such as EQ-5D, which is based on time trade-off
on expert opinion alone or expected outcomes, novel preference values from the 1990s, are similarly not derived
methods were used to base the scenarios on observed during the same year as costs but are presented in the same
evidence from the ECLIPSE trial, which increases the economic evaluation. Between these two particular price
reliability of the findings. years, inflation has been particularly low and therefore the
964 S. Sanghera et al.
lack of adjustment would introduce little if any bias. Fur- The results of this analysis present potentially important issues
thermore, by not changing the cost year we have presented about the use of the conventional measures from the extra-
results that are directly comparable to the cost utility welfarist perspective, EQ-5D and SF-6D, within the context of
analysis results. decision making for certain diseases such as menorrhagia. The
Given the limited availability of cost-benefit analyses cost-benefit analysis approach showed oral treatment to be the
currently reported in the literature, a strength of the current most efficient use of society’s resources. We have previously
article is that we have reported all relevant methods and shown [6] that the type of measure used to value outcomes has
results as explicitly as possible including additional infor- important implications for recommendations to decision
mation to that which is required by recommended guide- makers. To improve the generalisability and robustness of the
lines, such as CHEERS, to which published economic results, more research needs to be conducted using the WTP
evaluations are typically recommended to adhere. As far as approach on a larger sample size that more closely resembles
we are aware, the current study is the first cost-benefit the general population.
analysis to attempt to follow CHEERS guidelines [8] and Further research to explore the role of cost-benefit
the shortcomings of those guidelines in terms of their analysis and the use of the welfarist approach for certain
relevance to the full and clear reporting of economic conditions that affect non-health aspects of quality of life is
evaluations that take the form of a cost-benefit analysis required both generally by methodologists and specifically
have been apparent. in applied research for clinical conditions, such as
menorrhagia.
4.2 Comparison with Other Studies
Ethics Ethical approval was obtained from the National Research
Ethics Service Committee South West—Exeter. The research was
Very few cost-benefit analyses have been published. To the therefore performed in accordance with the ethical standards outlined
best of our knowledge, this is the only cost-benefit analysis in the 1964 Declaration of Helsinki.Written consent was obtained
focussing on menorrhagia. A recent cost-benefit analysis from the participants prior to their inclusion in the study.
has been carried out but in the area of spinal surgery in
Acknowledgments We thank the women who participated in the
Switzerland, where WTP was elicited from the ex-post study and the National Institute for Health Research for funding the
perspective using patient values [20]. The authors sug- research (Grant No: 02/06/02). J. K. Gupta reports honoraria received
gested that further methodological work be carried out on from Bayer (UK), the manufacturer of LNG-IUS (Mirena). All other
the use of ex-ante WTP values, as this perspective is rec- authors report no conflicts of interest.
ommended for publicly funded healthcare systems. Despite
Author Contributions SS, EF and TR conceived and designed the
the ex-ante perspective WTP and cost-benefit analysis be- study. SS developed and administered the questionnaire, carried out
ing theoretically preferred [9], WTP is typically elicited the data analysis, conducted the CBA and wrote the manuscript. EF
from the ex-post perspective [21]. and TR supported the questionnaire development and analysis. JG and
In terms of comparisons with other UK studies reporting JK facilitated data collection. All authors edited the manuscript. SS,
EF and TR are the guarantors of this work.
treatment recommendations for menorrhagia, in contrast to
our findings, the NICE guidelines recommend LNG-IUS as Open Access This article is distributed under the terms of the
the first-line treatment for menorrhagia [4]. Similarly, the Creative Commons Attribution-NonCommercial 4.0 International
economic evaluation alongside the ECLIPSE trial using License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
EQ-5D also found LNG-IUS the most cost-effective in- medium, provided you give appropriate credit to the original author(s)
tervention [6]. However, the recommendation for oral and the source, provide a link to the Creative Commons license, and
treatment to be first-line treatment in our cost-benefit indicate if changes were made.
analysis does correspond with the recommendation from
the economic evaluation alongside the ECLIPSE trial using
SF-6D [6]. Decision makers currently recommend EQ-5D
for the valuation of outcomes [1], therefore LNG-IUS
would be considered the most cost-effective treatment, References
despite other measures demonstrating that LNG-IUS is not
1. National Institute of Health and Clinical Excellence. Guide to the
the most cost-effective intervention. methods of technology appraisal 2013. London: National Institute
of Health and Clinical Excellence; 2013.
4.3 Implications and Further Research 2. Birch S, Donaldson C. Valuing the benefits and the costs of
healthcare programmes: where’s the ‘extra’ in extra-welfarism.
Soc Sci Med. 2003;56:1121–33.
The results of the current analysis are not attempting to 3. National Institute of Health and Clinical Excellence. Guide to the
overturn the NICE guideline recommendation but instead methods of technology appraisal. London: National Institute of
present an exploration of the use of an alternative measure. Health and Clinical Excellence; 2008.
Exploring Cost-Benefit Analysis in Menorrhagia 965
4. National Collaborating Centre for Women’s and Children’s 12. Whynes DK, Frew E, Wolstenholme JL. A comparison of two
Health. Heavy menstrual bleeding. London: Royal College of methods for eliciting contingent valuations of colorectal cancer
Obstetricians and Gynaecologists; 2007. screening. Health Econ. 2003;22(4):555–74.
5. Shapley M, Jordan K, Croft PR. Why women consult with in- 13. Smith RD. Construction of the contingent valuation market in
creased vaginal bleeding: a case–control study. Br J Gen Pract. healthcare: a critical assessment. Health Econ. 2003;12:609–28.
2002;52:108–13. 14. Smith RD. It’s not just what you do, it’s the way that you do it:
6. Sanghera S, Roberts T, Barton P, Daniels J, Middleton L, Gen- the effect of different payment card formats and survey admin-
nard L, Kai J, Gupta J. LNG-IUS vs. usual medical treatment for istration on willingness to pay for health gain. Health Econ.
menorrhagia: an economic evaluation alongside a randomised 2006;15:281–93.
controlled trial. PLoS One. 2014;9(3):e91891. doi:10.1371/ 15. Joint Formulary Committee. British National Formulary 62.
journal.pone.0091891. London, UK: BMJ Group and Pharmaceutical Press; 2011.
7. Sanghera S, Frew E, Kai J, Gupta J, Roberts TE. An assessment 16. Curtis L. Unit costs of health and social care: 2011. Canterbury:
of economic measures used in menorrhagia: a systematic review. Personal Social Service Research Unit; 2011.
Soc Sci Med. 2013;98:149–53. 17. Shackley P, Donaldson C. Should we use willingness to pay to
8. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, et al. elicit community preferences for healthcare? New evidence from
Consolidated health economic evaluation reporting standards using a ‘marginal’ approach. J Health Econ. 2002;21:971–91.
(CHEERS) statement. BMJ. 2013;346:f1049. 18. Shackley P, Donaldson C. Willingness to pay for publicly fi-
9. McIntosh E, Clarke PM, Frew EJ, Louviere JL. Applied methods nanced healthcare: how should we use the numbers? Appl Econ.
of cost-benefit analysis in health care. Oxford: Oxford University 2000;32:2015–21.
Press; 2010. 19. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation
10. Shaw RW, Brickley MR, Evans L, Edwards MJ. Perceptions of in clinical trials. Oxford: Oxford University Press; 2007.
women on the impact of menorrhagia on their health using multi- 20. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stod-
attribute utility assessment. Br J Obstet Gynaecol. dart GL. Methods for the economic evaluation of health care
1998;105:1155–9. programmes. 3rd ed. Oxford: Oxford University Press; 2005.
11. Gupta J, Kai J, Middleton L, Pattison H, Gray R. Levonorgestrel 21. Haefeli M, Elfering A, Mcintosh E, Gray A, Sukthankar A, et al.
intrauterine system vs medical therapy for menorrhagia. N Engl J A cost-benefit analysis using contingent valuation techniques: a
Med. 2013;368:128–37. feasibility study in spinal surgery. Value Health. 2008;11:575–88.